Development of recombinant vaccines in lactobacilli for elimination of salmonella.

Bioscience and microflora Pub Date : 2011-01-01 Epub Date: 2011-11-17 DOI:10.12938/bifidus.30.93
Akinobu Kajikawa, Shizunobu Igimi
{"title":"Development of recombinant vaccines in lactobacilli for elimination of salmonella.","authors":"Akinobu Kajikawa,&nbsp;Shizunobu Igimi","doi":"10.12938/bifidus.30.93","DOIUrl":null,"url":null,"abstract":"<p><p>Many Lactobacillus and Lactococcus strains are generally regarded as safe for consumption because they are utilized for food fermentation or inhabit the intestinal mucosa as commensals. Recently, vaccine delivery systems using lactic acid bacteria (LAB) have been under development. Our research group has been investigating the development of oral mucosal vaccines against Salmonella enterica serovar Enteritidis (SE) using Lactobacillus casei IGM393 as an antigen delivery vehicle. Recombinant lactobacilli expressing SE antigens, FliC, SipC, and OmpC, have been constructed and orally administered to mice. Antigen specific immune responses and protective immunity were elicited after the immunization. For adjuvant-delivery, IL-1β-secreting L. casei was also engineered and its effects evaluated in vitro and in vivo. This article reviews a novel approach to the elimination of Salmonella via the development of a vaccine in lactobacilli. </p>","PeriodicalId":90114,"journal":{"name":"Bioscience and microflora","volume":"30 4","pages":"93-8"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/fb/bifidus-30-093.PMC4103640.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioscience and microflora","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12938/bifidus.30.93","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/11/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Many Lactobacillus and Lactococcus strains are generally regarded as safe for consumption because they are utilized for food fermentation or inhabit the intestinal mucosa as commensals. Recently, vaccine delivery systems using lactic acid bacteria (LAB) have been under development. Our research group has been investigating the development of oral mucosal vaccines against Salmonella enterica serovar Enteritidis (SE) using Lactobacillus casei IGM393 as an antigen delivery vehicle. Recombinant lactobacilli expressing SE antigens, FliC, SipC, and OmpC, have been constructed and orally administered to mice. Antigen specific immune responses and protective immunity were elicited after the immunization. For adjuvant-delivery, IL-1β-secreting L. casei was also engineered and its effects evaluated in vitro and in vivo. This article reviews a novel approach to the elimination of Salmonella via the development of a vaccine in lactobacilli.

沙门氏菌乳酸菌重组疫苗的研制。
许多乳杆菌和乳球菌菌株通常被认为是安全的,因为它们被用于食物发酵或作为共生生物栖息在肠粘膜上。最近,利用乳酸菌(LAB)的疫苗递送系统正在开发中。本课课组一直在研究以干酪乳杆菌IGM393为抗原递送载体的肠沙门氏菌血清型肠炎(SE)口服黏膜疫苗的开发。构建了表达SE抗原FliC、SipC和OmpC的重组乳酸菌,并将其口服给鼠。免疫后可引起抗原特异性免疫反应和保护性免疫。在佐剂递送方面,还设计了分泌il -1β的干酪乳杆菌,并对其体外和体内效果进行了评价。本文综述了一种通过乳酸菌疫苗的开发来消除沙门氏菌的新方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信